Expression of Cancer-Testis Antigens in Salivary Gland Carcinomas with Reference to MAGE-A and NY-ESO-1 Expression in Adenoid Cystic Carcinoma.
Histopathology. 2017 Mar 28;:
Authors: Beppu S, Ito Y, Fujii K, Saida K, Takino H, Masaki A, Murase T, Kusafuka K, Iida Y, Onitsuka T, Yatabe Y, Hanai N, Hasegawa Y, Ijichi K, Murakami S, Inagaki H
BACKGROUND: Salivary gland carcinomas comprise a group of heterogeneous lesions with complex clinicopathological characteristics and distinct biological behaviors. However, recurrent or metastatic tumors are difficult to treat with currently available therapies. Cancer-testis antigens (CTAs) are detected in cancer cells but not in healthy normal tissues, with the exception of gametogenic tissues. CTAs are highly immunogenic proteins and thus represent ideal targets for cytotoxic T-lymphocyte-mediated specific immune therapy. However, clinicopathological significance of CTAs in salivary gland carcinomas remains unclear.
METHODS AND RESULTS: We used immunohistochemistry to examine the expression of four CTAs (MAGE-A, NY-ESO-1, CT7, and GAGE7) in various types of salivary gland carcinomas (n=95). When carcinoma cases were divided into low-grade and intermediate/high-grade types, NY-ESO-1 and CT7 were expressed more frequently in high/intermediate-grade carcinomas. We then focused on MAGE-A and NY-ESO-1 expression in a large cohort of adenoid cystic carcinomas (AdCCs, n=46). AdCC is one of the most common salivary gland carcinomas and usually has a fatal outcome. MAGE-A and NY-ESO-1 were frequently expressed in AdCC; specifically, MAGE-A was expressed in more than 60% of the AdCC cases. MAGE-A expression and tumor site (minor salivary gland) were identified as independent risk factors for loco-regional tumor recurrence.
CONCLUSIONS: These findings suggest that CTAs may be expressed in a variety of salivary gland carcinomas, especially in those with higher histological grades. In addition, MAGE-A, which is frequently expressed in AdCC cases, may be a useful prognostic factor for poorer loco-regional recurrence-free survival. This article is protected by copyright. All rights reserved.
PMID: 28370175 [PubMed - as supplied by publisher]